Methotrexate Viatris

Methotrexate, the active ingredient in Methotrexate Viatris, is an antimetabolite presented as a subcutaneous formulation for injection use. It is employed to treat autoimmune disorders, certain cancers, and ectopic pregnancy in adult patients. GNH USA supplies Methotrexate Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methotrexate acts on rapidly dividing cells and immune pathways, making it useful across several disease families. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: limits skin cell proliferation and improves plaque lesions. - Acute lymphoblastic leukemia: interferes with malignant cell DNA synthesis to achieve remission. - Non‑Hodgkin lymphoma: induces cytotoxicity in lymphoma cells to control disease spread. - Ectopic pregnancy: halts trophoblastic growth, allowing non‑surgical resolution.

Methotrexate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea or vomiting - Fatigue or malaise - Mucositis or mouth ulcers - Elevated liver enzymes - Alopecia or hair thinning - Skin rash or itching

Serious or Rare Side Effects: - Bone marrow suppression leading to pancytopenia - Severe hepatic toxicity or fibrosis - Pulmonary fibrosis or interstitial pneumonitis - Life‑threatening infections - Acute renal failure - Anaphylactic or severe hypersensitivity reactions

Before initiating therapy, clinicians should evaluate patient history and monitor laboratory parameters. - Pregnancy: avoid use unless clearly indicated, as it is teratogenic. - Liver disease: assess baseline liver function and monitor regularly. - Renal impairment: adjust dose or avoid if creatinine clearance is markedly reduced. - Concomitant immunosuppressants: increase risk of infection, require close observation. - Alcohol consumption: limit intake to reduce hepatic toxicity risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several drug classes, necessitating careful review of concomitant medications.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Penicillins and sulfonamides: may enhance hematologic toxicity. - Live vaccines: risk of severe infection due to immunosuppression. - Alcohol: potentiates hepatic injury. - Proton‑pump inhibitors: may raise plasma methotrexate levels.

Moderate Interactions (Monitor Closely): - Azathioprine or cyclosporine: additive immunosuppression. - Leflunomide: combined hepatotoxic potential. - Warfarin: may increase anticoagulant effect. - Phenytoin or carbamazepine: may alter methotrexate clearance. - Trimethoprim‑sulfamethoxazole: heightened risk of bone‑marrow suppression.